UroAlert - GU Oncology Weekly

November 06, 2024

Videos

Peer-to-Peer Clinical Conversations

MMAI Score Prognostic for Overall Survival in Oligometastatic Castration-Sensitive Prostate Cancer - Phuoc Tran & Tim Showalter

Phuoc Tran

Phuoc Tran and Tim Showalter join Zachary Klaassen to discuss two presentations examining the ArteraAI prostate test in oligometastatic castration-sensitive prostate cancer.

5-Year Survival Outcomes in Cisplatin-Ineligible Patients from EV-103 - Jonathan Rosenberg

Jonathan Rosenberg

Alicia Morgans hosts Jonathan Rosenberg to discuss the five-year outcomes from EV-103 Cohort A, examining enfortumab vedotin plus pembrolizumab in cisplatin-ineligible advanced urothelial cancer patients.

Beyond the Abstracts

Comparative Effectiveness of Bacillus Calmette-Guérin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naïve Intermediate-risk Non-muscle-invasive Bladder Cancer - Beyond the Abstract

Racial, Ethnic, and Socioeconomic Disparities in Rates of Stage IV Prostate Cancer After USPSTF Category "D" Recommendation Against Prostate-Specific Antigen Screening: A Retrospective Cohort Study - Beyond the Abstract

Conference Coverage

SCS AUA 2024: Should Veterans be Classified as High Risk for Prostate Cancer Screening: A Review of the Current Literature

SCS AUA 2024: Can We Predict Locally Advanced Disease Features with PSMA PET? Correlation of Molecular Imaging TNM with Pathological TNM in Radical Prostatectomy Specimen

SCS AUA 2024: Nephron Sparing Surgery for Localized Renal Masses

SCS AUA 2024: Adjuvant Immunotherapy in High-Risk Muscle Invasive Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

SCS AUA 2024: Exposures and Bladder Cancer Risk Among Military Veterans: A Systemic Review and Meta-Analysis

Physician-Scientist Review Articles

ESMO 2024 Quick Take Insights: A Focus on ARANOTE

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies.

A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer.

Prototol for the Prospective Sample Collection for Cancer of Bladder (ProCaB) Trial by the Cancer of the Bladder Leuven (CaBLe) Consortium.

Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer.

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study.

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer.

Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists.

Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now.

Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases.

Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials.

ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update.

Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer.

Prehabilitation in patients undergoing bladder cancer surgery - A systematic review and meta-analysis.

Single-Cell Transcriptomic Analysis to Build a Microenvironment-Aware Bladder Cancer Prognostic Model - Expert Commentary

Efficacy and Safety of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer After Immunotherapy - Expert Commentary

Penile & Urethral Cancers

Switching cisplatin to carboplatin in chemotherapy for metastatic penile cancer in a patient intolerant to cisplatin.

Human papillomavirus infection affects the immune microenvironment and antigen presentation in penile cancer.

Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) in Penile Squamous Cell Carcinoma-No Evidence for a Role in Carcinogenesis.

Renal Cancer

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors.

Immunotherapy and Tyrosine Kinase Inhibitor as a Bridge to Surgery for Clear Cell Renal Cell Carcinoma Metastases to the Thyroid: A Case Report and Literature Review.

NODESAFE Nomogram: A Novel Score System to Predict Lymph Node Involvement at the Time of Nephrectomy or Nodal Recurrence in Nonmetastatic Renal Cell Carcinoma.

Kidney cancer following occupational exposure to trichloroethylene: clinical case series and review of the literature.

Impact of Tumor Volume and Other Factors on Renal Function After Partial Nephrectomy

The future of cellular therapy for the treatment of renal cell carcinoma.

PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.

AI predictive modeling of survival outcomes for renal cancer patients undergoing targeted therapy.

Efficacy and Safety of Nivolumab With Ipilimumab in Elderly Patients With Advanced Renal Cell Carcinoma.

Prostate Cancer

Assessment of Different Castration Resistance Definitions and Staging Modalities in Metastatic Castration-Resistant Prostate Cancer.

AI-ADC: Channel and Spatial Attention-Based Contrastive Learning to Generate ADC Maps from T2W MRI for Prostate Cancer Detection.

Association of race with incidence, characteristics, and mortality from incidental prostate cancer: Analysis of two North American contemporary cohorts.

Statin use and oncological outcomes in a propensity-matched cohort of nonmetastatic castration resistant prostate cancer patients of the ARAMIS trial.

Assessing racial differences in time to subsequent treatment following androgen deprivation therapy among Veterans with prostate cancer.

Nutraceuticals target androgen receptor-splice variants (AR-SV) to manage castration resistant prostate cancer (CRPC).

First-Line Combination Treatment with PARP and Androgen Receptor-Signaling Inhibitors in HRR-Deficient mCRPC: Applying Clinical Study Findings to Clinical Practice in the United States - Beyond the Abstract

The Use of Novel Instrumented Socks to Detect Changes in Daily Life Mobility During an Exercise Intervention in Prostate Cancer Survivors Treated with Androgen Deprivation Therapy.

Validation of Biomechanical Computed Tomography for Fracture Risk Classification in Metastatic Hormone-sensitive Prostate Cancer.

The association between patient characteristics, psychological distress, and coping in the diagnostic phase of prostate cancer – A cross-sectional multicenter study

Black men's experiences of support following treatment for prostate cancer in England: A qualitative study.

Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial.

Pesticides and prostate cancer incidence and mortality: An environment-wide association study.

The Complex Challenge of Urosymphyseal Fistula and Pubic Osteomyelitis in Prostate Cancer Survivors.

County-level racial disparities in prostate cancer specific mortality from 2005 to 2020.

Evaluating the Importance of Practice-Level Factors on Adherence to Prostate Cancer Treatment Guidelines in Urology.

The TALAPRO-3 study design: a plain language summary.

In Major Win for Patients, CMS Adjusts Nuclear Medicine Reimbursement Policy, Expanding Access to Life-Saving Scans

Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.

Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial.

Germline genetic testing for prostate cancer: Ordering trends in the era of expanded hereditary cancer screening recommendations.

Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer.

Inhibition of PIM kinase in tumor associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy.

Oncogenic Alterations, Race, and Survival in US Veterans with Metastatic Prostate Cancer Undergoing Somatic Tumor Next Generation Sequencing.

ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.

PSMA PET/CT Accuracy in Diagnosing Prostate Cancer Nodes Metastases.

Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617.

Comparison of Posttherapy 4- and 24-Hour [177Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate Cancer.

FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.

Clinical, Pathologic, and Imaging Variables Associated with Prostate Cancer Detection by PSMA PET/CT and Multiparametric MRI.

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy - Beyond the Abstract

Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival - Beyond the Abstract

Testosterone Therapy in Men after Radical Prostatectomy for Organ-Confined, Low-Intermediate Prostate Cancer - Beyond the Abstract

Prostate Cancer Therapy Cardiotoxicity Map (PROXMAP) for Advanced Disease States: A Systematic Review and Network Meta-Analysis with Bayesian Modeling of Treatment Histories - Beyond the Abstract

Upper Tract Tumors

Robotic surgery of the urothelial carcinoma of the upper urinary tract single surgeon initial experience, 66 consecutive cases.

Imaging of Upper Tract Urothelial Carcinoma.

Risk factors of renal function deterioration after radical nephroureterectomy for upper tract urothelial carcinoma.

Testicular Cancer

Diagnostic and prognostic role of NLR in testicular cancer.

Chemokine Profile Is Different in Normal Testis Compared to Seminoma - Especially in Tumor Infiltrating Lymphocytes.

Refractory testicular germ cell tumors are highly sensitive to the targeting of polycomb pathway demethylases KDM6A and KDM6B.

Young adult Latino testicular cancer survivors: a pilot study of Goal-focused Emotion regulation Therapy (GET).

Radiological Assessment of Different Retroperitoneal Lymph Node Measurements in Stage 1 Testicular Cancer Patients: Impact on Clinical Stage and Treatment - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC